# Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes

Study · id `cardio:ct-nct06339086` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06339086](<https://clinicaltrials.gov/study/NCT06339086>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06339086

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 478 participants.

## Technical summary

Registry record NCT06339086. Randomized; no masking; primary purpose treatment. Start 2024-04 (anticipated); primary completion 2025-08-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 478 participants (planned count; ClinicalTrials.gov record NCT06339086, source copy `cardio:ctgov-nct06339086-2024-04-01`, retrieved 2026-10-26)
- Planned start: 2024-04 (anticipated) (ClinicalTrials.gov record NCT06339086, source copy `cardio:ctgov-nct06339086-2024-04-01`, retrieved 2026-10-26)
- Primary completion: 2025-08-30 (anticipated) (ClinicalTrials.gov record NCT06339086, source copy `cardio:ctgov-nct06339086-2024-04-01`, retrieved 2026-10-26)
- Completion: 2025-12-30 (anticipated) (ClinicalTrials.gov record NCT06339086, source copy `cardio:ctgov-nct06339086-2024-04-01`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06339086-2024-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Semaglutide Injection
- Intervention (Drug): Semaglutide Injection(Ozempic®)
- Intervention (Drug): Metformin
- Lead sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 737e7e3d2c5ea8b396087c7e81172659cdf6405541c44c1a3502fbeae28a28b6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
